investor login
contact
team
dedicated funds
news
portfolio
Older Posts >
< Newer Posts
Portfolio Company News
Search for:
FDA approves G1 Therapeutics’ COSELA™ (TRILACICLIB): The first and only myeloprotection therapy to decrease the incidence of chemotherapy-induced myelosuppression
February 18, 2021
Boston Immune Technologies and Therapeutics and BeiGene Enter into an Exclusive Option and License Agreement to Develop Novel TNFR2 Antagonists
February 18, 2021
BIAL Goes Global with New US Research Center and Acquisition of Promising Parkinson’s Disease Programs
October 1, 2020
Kymera Therapeutics Announces Pricing of Upsized Initial Public Offering
August 21, 2020
Older Posts >
< Newer Posts
contact
team
dedicated funds
news
home
portfolio
